
HLH DIAGNOSTIC GUIDELINES

(Updated October 2024)

Hemophagocytic Lymphohistiocytosis (HLH) and Macrophage Activation Syndrome (MAS) describe systemic hyperinflammatory syndromes that can develop in many inflammatory contexts. They can progress rapidly, and early identification and management are critical to prevent organ failure and mortality. (see Table 3)



^aPhysiology concerning for HLH/MAS may include:

• Pathologic processes, such as:

o Fever/SIRS/sepsis	o Bi/pancytopenia
o DIC	o Hepatitis

- Underlying diseases such as:
 - o Infections (EBV, Ehrlichia, Adenovirus, etc.)
 - o Rheumatic disease (Systemic JIA/Stills & SLE)
- Lab abnormalities, particularly:
 - o Very high ferritin

No individual test in Table 4 on page 5 is specific for HLH/MAS of any form. The dynamics/trend/trajectory of many tests is often as valuable as any individual value.

^bThe most common underlying causes of HLH/MAS are:

- Infection
 - o This is the most common trigger in older teens.
- Malignancy
- Rheumatic disease
- Genetic inborn error of immunity (primary HLH) o Particularly in younger children
 - o Familial HLH cytotoxicity defects
 - o Other inborn errors of immunity

Often, multiple causes combine to drive HLH/MAS.

continued>

1



INDEX FOR TABLES

TABLE	1: OVERARCHING PRINCIPLES OF HLH/MAS
Α	Systemic hyperinflammation is an immunopathological continuum; the characteristic clinical and laboratory findings are individually non-specific but when viewed collectively and longitudinally are recognizable. Diagnostic evaluation is warranted, and therapeutic intervention may be needed even if diagnostic criteria for HLH/MAS are not met.
в	Systemic hyperinflammation can be associated with hyperferritinemia and can progress to life-threatening HLH/MAS.
С	Systemic hyperinflammation and HLH/MAS can occur in nearly any inflammatory state, but certain predisposing conditions and/or inflammatory triggers warrant a high index of suspicion.
D	Investigating and treating modifiable contributors to systemic hyperinflammation and HLH/MAS are essential in the management of every patient.
E	HLH/MAS should be treated with an urgency based on both the degree of inflammation and extent of organ dysfunction; the goals of therapy are to prevent/limit immunopathology, preserve integrity of the ongoing diagnostic workup and minimize toxicity.
F	The evaluation and management of patients with systemic hyperinflammation suspected of having or progressing to HLH/MAS may benefit from consultation with experts in these disorders.

Source: Shakoory B, Geerlinks A, Wilejto M, et al. Ann Rheum Dis, doi:10.1136/, ard-2023-224123

continued>



TABLE 2: RECOGNIZABLE CLINICAL FEATURES/PATTERNS IN HLH/MAS

TABLE		
	FEATURE	CRITERIA*
1	Systemic inflammation (elevated or rising)	
	Fever	All
	CRP	None
	LDH	None
2	Hyperferritinemia (elevating or rising)	All
3	Cytopenias (low or dropping)	
	Platelet count	All
	Leucocyte count (particularly neutrophil count)	HLH04, HScore
	Hemoglobin	HLH04, HScore
4	Disseminated intravascular coagulopathy	
	Increased D-dimer	None
	Low/dropping fibrinogen	All
	Prolonged PT/INR, PTT	None
5	Liver dysfunction	
	Hepatomegaly	HScore
	Increased ALT, AST, bilirubin	HLH04, HScore
	Increased triglycerides	All
6	Splenomegaly	HLH04, HScore
7	CNS dysfunction	
	Encephalitis, encephalopathy, altered mental status, seizure	None
	CSF pleocytosis, elevated CSF protein, increased ICP	None
	Radiologic evidence of CNS inflammation	None

Source: Shakoory B, Geerlinks A, Wilejto M, et al. Ann Rheum Dis, doi:10.1136/, ard-2023-224123

*Criteria

• HLHO4 (revised): Developed to classify infants and children for treatment trials targeting pediatric patients with genetic causes of HLH/MAS (Henter et al., Pediatr Blood Ca 2007)

• MAS16: Developed to classify MAS in patients with known or strongly suspected Systemic Juvenile Idiopathic Arthritis (sJIA). (Ravelli et al., Arthritis Rheumatol 2016)

• **Hscore**: Developed in adults with primarily malignancy or infection-associated HLH. (Fardet, Arthritis Rheumatol 2014)

continued>

3



Children's Hospital of Philadelphia Immune Dysregulation Program

TABLE 3: PROPORTION OF ATTRIBUTABLE HLH/MAS CASES BY PRIMARY CONTRIBUTOR				
	Median % (min, r	Median % (min, max)		
	Pediatric	Adult		
Genetic cause				
Genetic HLH disorders	12% (3-46)	Rare		
Other inborn errors of immunity	6% (2-18)	Rare		
Predisposing conditions				
Rheumatological	10% (2-26)	8% (2-26)		
Malignancies	5% (2-19)	46% (26-73)		
Acute triggers				
All-cause infections	57% (9-88)	27% (9-75)		
Viral infections	57% (18-80)	14% (2-33)		
Bacterial infections	10% (3-58)	14% (2-45)		
Idiopathic				
Unknown etiology	42% (17-49)	18% (4-40)		

Source: Shakoory B, Geerlinks A, Wilejto M, et al. Ann Rheum Dis, doi:10.1136/, ard-2023-224123

continued>



HLH Diagnostic Guidelines (continued from page 4)

Monitoring key: F: Frequent (e.g., daily) I: Intermittent (e.g., weekly) R: Rarely (e.g., monthly) PRN: As needed

TEST	TREND IN HLH/MAS	BIOLOGY	MONITORING	CAVEATS
CBC		I	I	1
Neutrophil count	↓		F	Glucocorticoid demargination
Lymphocyte count	↓	Affected by marrow production, proliferation, tissue	F	
Hemoglobin	↓	sequestration and consumption	F	
Platelet count	¥	I I I	F	
	OMARKERS			
CRP	1	Hepatic release in response to IL-6	F	Blunted by IL-6 blocking drugs
Ferritin	1	Macrophage/ Hepatocyte activation	F	by iron overload and hepatic failure
ESR	↑ ↓	Falls with fibrinogen consumption	Ι	by IVIg, dialysis
LDH	1	Cellular death/injury	Ι	with hemolysis, TMA
Soluble IL-2Ra	1	T-cell activation	I, R	
CXCL9	1	Chemokine induced by IFNy	I, R	
IL-18	1	Inflammasome- activated, induces IFNy	PRN	
LIVER FUNCTION T	ESTS	'		'
ALT, AST, bilirubin	1	Hepatocyte injury	F	
Triglycerides	¥	Cytokine inhibition of lipoprotein lipase	R, PRN	Fasting
Albumin	¥	Vascular leak /third spacing	F	

Source: Shakoory B, Geerlinks A, Wilejto M, et al. Ann Rheum Dis, doi:10.1136/, ard-2023-224123

5

continued>

Children's Hospital of Philadelphia Immune Dysregulation Program Monitoring key: F: Frequent (e.g., daily) I: Intermittent (e.g., weekly) R: Rarely (e.g., monthly) PRN: As needed

TABLE 4: LABORATORY AND BIOMARKER TESTING IN HLH/MAS (continued)					
COAGULOPATHY TESTS					
Fibrinogen	¥	Fibrinogen	F		
D-dimer	1	consumption/fibrin degradation	F, I		
PT/INR/PTT	1	Factor consumption	F	Heparin effects	
CNS TESTS					
Brain imaging	abnormal	Inflammation of white or gray matter, meninges, hypoxia	PRN		
CSF studies	¢	Pleocytosis and/or high protein > CNS inflammation	PRN		

Source: Shakoory B, Geerlinks A, Wilejto M, et al. Ann Rheum Dis, doi:10.1136/, ard-2023-224123

continued>



SCREENING FOR HLH AND PROPOSED ORDER SET

HLH/Hyperinflammatory screening and monitoring

CBC with Diff CRP ESR Comprehensive metabolic panel Ferritin Fibrinogen Triglycerides Proinflammatory cytokine panel (CHOP) D-Dimer LDH Soluble Interleukin-2 Receptor alpha (IL-2) Ra (aka CD25) PT/INR PTT IL-18 CXCL9 Consult to Immune Dysregulation IP team.

TMA labs: sC5B9, ADAMTS-13 activity w/reflex to inhibitor & Ab (Machaon)

To learn more, contact the Immune Dysregulation Program at 215-590-6706 or visit chop.edu/immune-dysregulation.

HLH/Hyperinflammation etiology (select)

CD107a mobilization Perforin/Granzyme B flow cytometry SAP/XIAP flow cytometry Adenovirus PCR EBV PCR Sorted EBV PCR o To determine if EBV is present in B-cells, T-cells, and/or NK cells sorted from the same sample. o Check all subsets you're interested in sending. o Call the immunogenetics lab at ext. 45648 to let them know. EBV serology CMV PCR

CMV serology HSV if neonate HLH molecular genetic panel (collapsible) o Machaon o CHOP o Invitae

Save our specimen.

o Rainbow tube = small volume (all of the tubes saved 24-48 hours): - Serum separator - EDTA - Sodium heparin - Lithium plasma 🗖

©2024 The Children's Hospital of Philadelphia, all rights reserved. Use of this Site (as defined below) is subject to the Terms of Use (chop.edu/pages/terms-use). This Immune Dysregulation Program "Resources for Professionals" and all its contents ("Site") are solely intended to be educational resources for healthcare professionals. Accordingly, the Site is not intended to constitute medical advice or treatment, or to create a doctor-patient relationship between/among The Children's Hospital of Philadelphia ("CHOP"), its physicians and the individual patients. Any use of the Site for commercial purpose is strictly prohibited. CHOP does not represent or warrant that the Site and any information contained therein are in every respect accurate or complete, or that one or more of them apply to a particular patient or medical condition. The Site is based upon publicly available medical evidence (which is not based exclusively on randomized controlled clinical trials) and/or a consensus of medical paracetical propose is CHOP. It is current at the time of publication. The Site is intended to be aguide. CHOP is not responsible for any errors or missions or for any outcomes a patient might experience where a clinician consulted any information provided by the Site is nonnection with providing care for that patient. Any use of or reliance on the Site is is nonnection with providing care for that patient. Any use of or reliance on the Site is is nonnection with providing care for that patient. Any use of or reliance on the Site is nonnection with providing care for that patient. Any use of or reliance on the Site is nonnection with providing care for that patient. Any use of or reliance on the Site is nonnection with providing care for that patient. Any use of or reliance on the Site is successful to a site of or non site of any outcomes a patient might experience where a clinician consulted any information provided by the Site is nonnection with providing care for that patient. Any use of or reliance on the Site is inten



Children's Hospital of Philadelphia Immune Dysregulation Program